Ideas

Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: Pioglitazone (trade name: Actos), an antihyperglycemic drug, increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via down regulation of its target gene, 2/January/2017, 8.26 am
Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: Pioglitazone (trade name: Actos), an antihyperglycemic drug, increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via down regulation of its target gene, 2/January/2017, 8.26 am 150 150 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance: Given that: (1) Cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Life-extension therapy: Rosiglitazone, an antidiabetic medication, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 2/January/2017, 6.15 am
Life-extension therapy: Rosiglitazone, an antidiabetic medication, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 2/January/2017, 6.15 am 150 150 Dr Boomi's Genom-2-Discovery Center

What they say? A study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1…

read more

Vitamin-based PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: δ-tocotrienol (a form of Vitamin-E) inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene 1/January/2017, 11.45 pm
Vitamin-based PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: δ-tocotrienol (a form of Vitamin-E) inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene 1/January/2017, 11.45 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA shows…

read more

Immune enhancement therapy: Long ncRNA-TUG1 (taurine-upregulated gene) increases SOX2 expression and promotes innate immunity against bacterial infection via down-regulation of its target gene, 1/January/2017, 11.28 pm
Immune enhancement therapy: Long ncRNA-TUG1 (taurine-upregulated gene) increases SOX2 expression and promotes innate immunity against bacterial infection via down-regulation of its target gene, 1/January/2017, 11.28 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:   A recent study from the Institute of Biophysics, Chinese Academy of Sciences, Beijing, China shows that “Sox2 functions as a sequence-specific DNA sensor in neutrophils to initiate innate…

read more

Molecular therapy for triple-negative breast tumors: MiR-29b increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 1/January/2017, 11.11 pm
Molecular therapy for triple-negative breast tumors: MiR-29b increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 1/January/2017, 11.11 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA shows that “PIM1 kinase inhibition as…

read more

Molecular therapy for Bone disorders: SCYL1-BP1 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 1/January/2017, 11.00 pm
Molecular therapy for Bone disorders: SCYL1-BP1 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 1/January/2017, 11.00 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A study from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA has reported that “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis…

read more
Start Typing